Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet A Dunn

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
BMC Medical Research Methodology|July 20, 2017
A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelinesPankaj Mistry, Janet A Dunn, Andrea Marshall
BMJ (Clinical Research Ed.)|March 4, 2008
National randomised controlled trial is neededPeter K Donnelly, Louise Hiller, Janet A Dunn
The Journal of Steroid Biochemistry and Molecular Biology|January 18, 2019
Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanismJanet A Dunn, Kieran Jefferson, Donald MacDonald, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 16, 2016
Prevalence and treatment of hypovitaminosis D in the haemodialysis population of CoventrySharon A Huish, Simon Fletcher, Janet A Dunn, et al.
BMC Public Health|March 29, 2012
UK ethnicity data collection for healthcare statistics: the South Asian perspectiveGulnaz Iqbal, Mark Rd Johnson, Ala Szczepura, et al.
BJU International|August 27, 2004
Socio-economic deprivation and survival in bladder cancerGulnaz Begum, Janet A Dunn, Richard T Bryan, et al.
Endocrine Connections|September 14, 2021
Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1α-hydroxylase the only problem?Sharon A Huish, Carl Jenkinson, Janet A Dunn, et al.
Pharmacoeconomics|September 6, 2015
The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 TrialDavid M Meads, Andrea Marshall, Claire T Hulme, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myeloma - Authors' replyMark T Drayson, Stella Bowcock, Tim Planche, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
BMC Medical Research Methodology|July 20, 2017
A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelinesPankaj Mistry, Janet A Dunn, Andrea Marshall
BMJ (Clinical Research Ed.)|March 4, 2008
National randomised controlled trial is neededPeter K Donnelly, Louise Hiller, Janet A Dunn
The Journal of Steroid Biochemistry and Molecular Biology|January 18, 2019
Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanismJanet A Dunn, Kieran Jefferson, Donald MacDonald, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 16, 2016
Prevalence and treatment of hypovitaminosis D in the haemodialysis population of CoventrySharon A Huish, Simon Fletcher, Janet A Dunn, et al.
BMC Public Health|March 29, 2012
UK ethnicity data collection for healthcare statistics: the South Asian perspectiveGulnaz Iqbal, Mark Rd Johnson, Ala Szczepura, et al.
BJU International|August 27, 2004
Socio-economic deprivation and survival in bladder cancerGulnaz Begum, Janet A Dunn, Richard T Bryan, et al.
Endocrine Connections|September 14, 2021
Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1α-hydroxylase the only problem?Sharon A Huish, Carl Jenkinson, Janet A Dunn, et al.
Pharmacoeconomics|September 6, 2015
The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 TrialDavid M Meads, Andrea Marshall, Claire T Hulme, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myeloma - Authors' replyMark T Drayson, Stella Bowcock, Tim Planche, et al.
Lancet (London, England)|February 17, 2020
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' replyHelena M Earl, Louise Hiller, Chris Plummer, et al.
Pageof 6